Integrating both Europe and Asia in your clinical development plan can significantly enhance the value of your assets: generate diverse clinical evidence, strengthen discussions with regulators and partners, and create optionality for future licensing, co-development and commercialization opportunities across these 2 regions. By incorporating this strategy from Phase Ib/IIa onwards, companies can reduce development risk while maximizing the global potential of their asset.